BlackRock
EVFM

BlackRock’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

BlackRock’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-234,225
Closed -$265K – 6056
2022
Q2 		$265K Sell
234,225
-26,449
-10% -$43.6K ﹤0.01% 4964
2022
Q1 		$1.33M Sell
260,674
-778
-0.3% -$4.89K ﹤0.01% 4562
2021
Q4 		$1.47M Buy
261,452
+3,573
+1% +$30.4K ﹤0.01% 4517
2021
Q3 		$2.86M Buy
257,879
+31,498
+14% +$396K ﹤0.01% 4169
2021
Q2 		$3.84M Sell
226,381
-147,473
-39% -$2.8M ﹤0.01% 3991
2021
Q1 		$9.81M Buy
373,854
+26,275
+8% +$1.19M ﹤0.01% 3585
2020
Q4 		$12.6M Buy
347,579
+17,317
+5% +$626K ﹤0.01% 3257
2020
Q3 		$11.7M Buy
330,262
+141,340
+75% +$6.14M ﹤0.01% 3138
2020
Q2 		$8.02M Sell
188,922
-340,940
-64% -$23M ﹤0.01% 3309
2020
Q1 		$42.3M Buy
529,862
+478,976
+941% +$38.3M ﹤0.01% 2156
2019
Q4 		$4.71M Buy
50,886
+102
+0.2% +$8.61K ﹤0.01% 3522
2019
Q3 		$3.84M Buy
50,784
+1,556
+3% +$119K ﹤0.01% 3557
2019
Q2 		$4.9M Buy
49,228
+48,299
+5,199% +$3.74M ﹤0.01% 3536
2019
Q1 		$49K Sell
929
-59
-6% -$3.19K ﹤0.01% 4482
2018
Q4 		$62K Buy
988
+9
+0.9% +$495 ﹤0.01% 4444
2018
Q3 		$59K Buy
979
+471
+93% +$20.4K ﹤0.01% 4531
2018
Q2 		$21K Buy
508
+432
+568% +$34K ﹤0.01% 4674
2018
Q1 		$8K Sell
76
-18
-19% -$2.31K ﹤0.01% 4679
2017
Q4 		$17K Buy
94
+2
+2% +$226 ﹤0.01% 4591
2017
Q3 		$4K Buy
92
+5
+6% +$193 ﹤0.01% 4778
2017
Q2 		$5K Sell
87
-15
-15% -$2.63K ﹤0.01% 4802
2017
Q1 		$15K Buy
+102
New +$13.2K ﹤0.01% 4662

Other funds holding EVFM

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

BlackRock's EVFM Position: Q3 2022 in Review

BlackRock sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 234,225 shares — an estimated $265K sold.

BlackRock first reported a position in EVFM in Q1 2017 and held it in 22 quarters. The position peaked at $42.3M in Q1 2020. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

  • BlackRock reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • BlackRock sold 234,225 Evofem Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $265K.
  • BlackRock first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2017 and held it in 22 quarters.
  • BlackRock's Evofem Biosciences, Inc. Common Stock position peaked at $42.3M in Q1 2020.
  • 8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on BlackRock's 13F filing for Q3 2022, filed 14 Nov 2022.